MANUSCRIPTS

  1. He, H et al. Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen. British Journal of Haematology, 2018, 181, 122–151.
    https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.14497
  2. Kastritis, E, at al. Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer Journal (2018) 8:46.
    https://europepmc.org/articles/pmc5967299
  3. Arana, P, at al. Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials. Leukemia (2018) 32, 971–978.
    https://www.nature.com/articles/leu2017320
  4. Mithraprabhu, S, at al. Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma.
    Int. J. Mol. Sci. 2018, 19(7), 1858.
    http://www.mdpi.com/1422-0067/19/7/1858
  5. Misiewicz-Krzeminska,I, et al. A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility. Haematologica 2018 Volume 103(5):880-889.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927993/
  6. Rojas, A, at al. Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma. Clin Cancer Res; 23(21) November 1, 2017. http://clincancerres.aacrjournals.org/content/23/21/6602.long
  7. Flores-Montero J, Paiva B, Orfao, A, et al. Next generation flow (NGF) for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. 2017 Oct;31(10):2094-2103. doi: 10.1038/leu.2017.29. Epub 2017 Jan 20.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629369/
  8. Jelinek, T et al. Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer J. 2017 Oct 20;7(10):e617. doi: 10.1038/bcj.2017.90. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678219/
  9. Mithraprabhu, S, Spencer, A et al. Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma. Leukemia. 2017 Aug;31(8):1695-1705. doi: 10.1038/leu.2016.366. Epub 2016 Nov 30.
    https://www.ncbi.nlm.nih.gov/pubmed/27899805
  10. Hillengass, J et al. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer J. 2017 Aug 25;7(8):e599. doi: 10.1038/bcj.2017.78.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596388/
  11. Lahuerta JJ, Paiva B, et al. Depth of response in multiple myeloma: a pooled analysis of 609 patients enrolled in three PETHEMA/GEM clinical trials. J Clin Oncol. 2017 Sep 1;35(25):2900-2910. doi: 10.1200/JCO.2016.69.2517. Epub 2017 May 12.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568033/
  12. Roshal M, Flores-Montero, JA, et al. MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood Advances 2017 1:728-732; doi:
    https://doi.org/10.1182/bloodadvances.2016003715.
  13. Mishima Y, Paiva B, Ghobrial I, et al. The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017 Apr 4;19(1):218-224.
    http://www.cell.com/cell-reports/pdf/S2211-1247(17)30357-1.pdf
  14. Quwaider, D, at al. DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma. J Hematol Oncol. 2017; 10: 92. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395780/
  15. Seckinger, A, et al. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. Cancer Cell 31, 396–410, March 13, 2017.
    https://www.cell.com/cancer-cell/fulltext/S1535-6108(17)30016-8
  16. Paiva, B, et al. Differentiation stage of myeloma plasma cells: biological and clinical significance. Leukemia. 2017 February ; 31(2): 382–392. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439510/
  17. Halvarsson B-M, Wihlborg A-K, et al. Direct evidence for a polygenic etiology in familial multiple myeloma. Blood Advances. 2017 1:619-623
    http://www.bloodadvances.org/content/1/10/619
  18. Paiva B, Merino J and San Miguel JF. Utility of flow cytometry studies in the management of patients with multiple myeloma. Curr Opin Oncol 2016, 28:511–517.
    https://journals.lww.com/co-oncology/Fulltext/2016/11000/Utility_of_flow_cytometry_studies_in_the.9.aspx
  19. Paiva B, et al. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood. 2016;127(25):3165-3174. http://www.bloodjournal.org/content/127/25/3165
  20. Paiva B, et al. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. Blood. 2016;127(24):3035-3039. http://www.bloodjournal.org/content/bloodjournal/127/24/3035.full.pdf
  21. Paiva B, et al. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood. 2016;127(15):1896-1906. http://www.bloodjournal.org/content/127/15/1896
  22. Flores-Montero J, Paiva B, Orfao, A, et al. Next generation flow (NGF) for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. 2017 Oct;31(10):2094-2103. doi: 10.1038/leu.2017.29. Epub 2017 Jan 20.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629369/
  23. Pojero F, Flores-Montero J, Sanoja L, Perez JJ, Puig N, Paiva B, Bottcher S, van Dongen JM, and Orfao A on behalf of the Euroflow group. Utility of CD54, CD229, CD319 for the Identification of Plasma Cells in Patients with Clonal Plasma Cell Diseases. Cytometry Part B (Clinical Cytometry) 201690B:91–100.
    http://onlinelibrary.wiley.com/doi/10.1002/cyto.b.21269/epdf
  24. Paiva B, van Dongen JM, and Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood 2015; 125: 3059-3068
    http://www.bloodjournal.org/content/bloodjournal/125/20/3059.full.pdf
  25. Paiva B, Chandia M, Puig N, Vidriales MD, Perez JJ, Lopez-Corral L, Ocio EM, Garcia-Sanz R, Gutierrez NC, Jimenez-Ubieto A, Lahuerta JJ, Mateos MV, and San Miguel JF. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. Haematologica Feb 2015, 100 (2) e53-e55.
    http://www.haematologica.org/content/100/2/e53.full.pdf
  26. Matarraz S, Paiva B, Díez-Campelo M, Bárrena S, Jara-Acevedo M, Gutiérrez ML, Sayagués JM, Sánchez ML, Bárcena P, Garrastazul MP, Berruezo MJ, Duran JM, Cerveró C, García-Erce JA, Florensa L, Méndez GD, Gutierrez O, Del Cañizo MC, van Dongen JJ, San Miguel JF, Orfao A. Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patientspredict for myelodysplasia-associated cytogenetic alterations. Leukemia. 2014 Aug;28(8):1747-50.
    http://www.nature.com/leu/journal/v28/n8/full/leu2014103a.html
  27. Matarraz S, et al. Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide? Haematologica October 2012 97: 1608-1611
    http://www.haematologica.org/content/97/10/1608

 

ABSTRACTS

  1. Mateos MV, et al. Curative Strategy  for High-Risk Smoldering Myeloma (GEM-CESAR): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd
    https://ash.confex.com/ash/2017/webprogram/Paper102714.html
  2. Sanoja-Flores Luzalba, Flores-Montero Juan, and Orfao Alberto1 on behalf of the EuroFlow Consortium and the International Myeloma Foundation. Frequency and number of clonal plasma cells in peripheral blood (PB) in plasma cell neoplasm (PCN) by Next Generation Flow. XV Congress of Iberican Society of Cytometry. May 2017.  (poster presentation) *link to follow*
  3. Misiewicz-Krzeminska I, et al. Quantification of proteins from CD138-purified myeloma cells using the capillary nano-immunoassay technology is a better predictor of survival than the corresponding gene expression value. 16th International Myeloma Workshop, March 1-4, 2017.
  4. Hillengass, J et al. Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders – a Study of the International Myeloma Working Group. Blood 2016 128:4468.
    http://www.bloodjournal.org/content/128/22/4468
  5. Spencer A, Mithraprabhu S, Ramachandran M, Klarica D, Hocking J, Mai L, Walsh S, Broemeling D, Marziali A, Kalff A, Wiggin M, Durie BGM, and Khong TT. Evaluation of Circulating Tumour DNA for the Mutational Characterisation of Multiple Myeloma. Blood 2015 126:368.
    http://www.bloodjournal.org/content/126/23/368
  6. Misiewicz-Krzeminska I, et al. Quantification of Cyclin D1, Cyclin D2, Ikaros, Aiolos, and Cerebelon Proteins by Capilary Immunoassay in Patients with Newly Diagnosed Multiple Myeloma and Analysis of their Impact on Patient Survival. EHA21 Abstract Book (2016).
    http://learningcenter.ehaweb.org/eha/2016/21st/133252/irena.misiewicz-krzeminska.quantification.of.cyclin.d1.cyclin.d2.ikaros.aiolos.html?f=p6m3e968o12153
  7. Kubiczkova-Besse L, Drandi D, Sedlarikova L, Oliva S,  Gambella M, Omedè P, Adam Z, Pour L, Sevcikova S, Boccadoro M, Palumbo A, Hajek R. Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients. Blood 2014 124:3423 
    http://www.bloodjournal.org/content/124/21/3423

 

PRESENTATIONS

  1. iStopMM – A Nationwide Screening Study of MGUS
    2017 ASH Conference – Friday, December 8, 2017, 3:45 PM-5:05 PM
    Sigurður Yngvi Kristinsson, MD, PhD
    Faculty of Medicine, University of Iceland, Reykjavik, Iceland